1. Show article details.

    Reckitt's Personal Lubricants Buy May Lessen Competition -UK Regulator

    DJ Business News – 2:51 AM ET 05/22/2015

    LONDON--U.K. consumer goods company Reckitt Benckiser Group PLC's (RBGPF) anticipated acquisition of the K-Y brand could lead to higher prices for personal lubricants, the U.K.' s competition regulator said Friday. Reckitt, which makes Durex condoms and already sells lubricant under the Durex brand, signed an agreement in March 2014 to buy the K-Y brand of lubricants from Johnson& Johnson subsidiary McNeil-PPC Inc. for an undisclosed sum. The U.K.' s Competition and Markets Authority...

  2. Show article details.

    BRIEF-CMA outlines concerns over Reckitt Benckiser's acquisition of K-Y brand

    Reuters – 2:26 AM ET 05/22/2015

    Competition Market Authority: * Reckitt Benckiser's anticipated acquisition of K-Y brand could lead to higher prices for personal lubricants. * Group provisionally believes that on balance merger could lead to substantial reduction in competition, possibly through higher prices. * Inquiry group extended inquiry timetable by eight weeks so it must now publish its final decision by 18 August, 2015.

  3. Show article details.

    China Diabetes Management Devices Market Growth to be Driven by Rise in Sedentary Lifestyle and Life Expectancy and Patient Compliant Technologies Especially for Insulin Pump and CGM

    PR Newswire – 10:40 AM ET 05/20/2015

    LONDON and NEW YORK, May 20, 2015 China, with 100 million diabetics has already outpaced other nations in terms of number of diabetics.

  4. Show article details.

    BRIEF-Novo Nordisk sells auto-immune licence to J&J unit

    Reuters – 10:12 AM ET 05/20/2015

    Novo Nordisk A/S. * Says Janssen Biotech Inc will acquire licence to further develop and commercialise a clinical programme focused on therapy within auto-immune diseases. * The programme targets modulation of certain immune cells via a cell surface receptor. * Terms of the agreement have not been disclosed. * The agreement is subject to final clearance by U.S. regulators.

  5. Show article details.

    J&J Expects to File at Least 10 New Drugs

    DJ Business News – 9:05 AM ET 05/20/2015

    Johnson& Johnson said Wednesday that its Janssen Pharmaceutical segment plans to file for regulatory approval of at least 10 new drugs by 2019, each with the potential to exceed $1 billion in revenue. The company also said it plans more than 40 line extensions of existing and new medicines. We look forward to continuing to drive above-industry growth with our current in-market portfolio and next wave of medicines, said Joaquin Duato, world-wide pharmaceuticals chairman.

  6. Show article details.

    Johnson & Johnson Says It Will File at Least 10 New Drugs by 2019

    DJ Business News – 8:32 AM ET 05/20/2015

    Johnson& Johnson said Wednesday that its Janssen Pharmaceutical segment plans to file for regulatory approval of at least 10 new drugs by 2019, each with the potential to exceed $1 billion in revenue. The company also said it plans more than 40 line extensions of existing and new medicines. "We look forward to continuing to drive above-industry growth with our current in-market portfolio and next wave of medicines," said Joaquin Duato, world-wide pharmaceuticals chairman.

  7. Show article details.

    Johnson & Johnson to file 10 new drugs by 2019 that may have more than $1 bln revenue

    MarketWatch – 7:39 AM ET 05/20/2015

    Johnson& Johnson said Wednesday it expects to file more than 10 new pharmaceutical products by 2019, each with the potential to generate revenue of more than $1 billion. In a statement released ahead of an analyst meeting, the consumer goods giant said its pharmaceutical division has launched 14 new products since 2009, seven of which already exceed or are on track to have sales of more than $1 billion in 2015. The unit focuses on five areas: immunology, infectious diseases&...

  8. Johnson & Johnson says new products have potential to exceed $1 bln revenue

    MarketWatch – 7:32 AM ET 05/20/2015
  9. Johnson & Johnson says to file more than 10 new products by 2019

    MarketWatch – 7:31 AM ET 05/20/2015
  10. Show article details.

    Johnson & Johnson Pharmaceutical Segment to Continue Driving Above-Industry Growth with Plans to File More than 10 New Products by 2019, Each with Potential to Exceed $1 Billion in Revenue

    PR Newswire – 7:30 AM ET 05/20/2015

    NEW BRUNSWICK, N.J., May 20, 2015 At a meeting today with industry analysts, senior leaders from the Janssen Pharmaceutical Companies of Johnson & Johnson  will announce plans to file for regulatory approval of more than 10 new products between 2015 and 2019, each with the potential to exceed $1 billion in revenue1, as well as more than 40 line extensions of existing and new medicines.

  11. Show article details.

    Johnson & Johnson to Invest in Achillion

    DJ Business News – 6:05 PM ET 05/19/2015

    Johnson& Johnson will develop and sell Achillion Pharmaceuticals Inc. (ACHN) s hepatitis C drugs and invest $225 million in Achillion, in a combined deal valued at about $1.1 billion, the companies said on Tuesday. Under the exclusive global collaboration and licensing agreement, Johnson& Johnson' s Janssen Pharmaceuticals Inc. subsidiary becomes responsible for all costs of developing and selling the treatment regimens. Achillion, meanwhile, is eligible for tiered royalty...

  12. Show article details.

    Johnson & Johnson and Achillion in $1.1 Billion Tie-Up

    DJ Business News – 5:58 PM ET 05/19/2015

    Johnson& Johnson will develop and sell Achillion Pharmaceuticals Inc.' s hepatitis C drugs and invest $225 million in Achillion, in a combined deal valued at about $1.1 billion, the companies said on Tuesday. Under the exclusive global collaboration and licensing agreement, Johnson& Johnson's Janssen Pharmaceuticals Inc. subsidiary becomes responsible for all costs of developing and selling the treatment regimens. Achillion, meanwhile, is eligible for tiered royalty...

  13. Show article details.

    Johnson & Johnson's Schizophrenia Drug Wins FDA Approval

    DJ Business News – 9:45 AM ET 05/19/2015

    Food and Drug Administration approved Johnson& Johnson' s latest schizophrenia treatment, which the company says is the longest dosing interval available for patients with the condition. Janssen Pharmaceuticals Inc., a unit of Johnson& Johnson, developed the atypical antipsychotic Invega Trinza, which was granted priority review in January. The companies said that patients must first be treated with Invega Sustenna, a once-monthly injection, for at least four months...

  14. Show article details.

    Johnson & Johnson's Schizophrenia Drug Wins FDA Approval

    DJ Business News – 9:28 AM ET 05/19/2015

    Food and Drug Administration approved Johnson& Johnson's latest schizophrenia treatment, which the company says is the longest dosing interval available for patients with the condition. Janssen Pharmaceuticals Inc., a unit of Johnson& Johnson, developed the atypical antipsychotic Invega Trinza, which was granted priority review in January. The companies said that patients must first be treated with Invega Sustenna, a once-monthly injection, for at least four months before...

  15. Show article details.

    U.S. FDA warns on newer class of type 2 diabetes drugs

    Reuters – 11:06 AM ET 05/15/2015

    The U.S. Food and Drug Administration on Friday warned that a widely used newer class of type 2 diabetes drug sold by AstraZeneca (AZN), Johnson & Johnson (JNJ) and Eli Lilly (LLY) in partnership with Boehringer Ingleheim may a cause dangerously high levels of blood acids that could require hospitalization.

  16. Show article details.

    Navy's new retention tool: longer maternity leave

    MarketWatch – 7:39 AM ET 05/14/2015

    Navy's plan to double paid maternity leave to 12 weeks next year makes it the latest in a string of employers that are improving pay or benefits for workers. The Navy's intent, which doesn't include fathers, was announced Wednesday in a speech by Navy Secretary Ray Mabus and will need to be approved by Congress. It's unclear whether other parts of the Armed Services will seek to copy the plan.

  17. Show article details.

    Four drugmakers escape Chicago painkiller marketing lawsuit

    Reuters – 12:44 PM ET 05/08/2015

    A U.S. judge on Friday dismissed a lawsuit filed by the city of Chicago in federal court against four drugmakers accused of promoting painkiller addiction through deceptive marketing, though the case will continue against Oxycontin maker Purdue Pharma LP.

  18. Show article details.

    PRESS DIGEST- New York Times business news - May 7

    Reuters – 12:34 AM ET 05/07/2015

    The following are the top stories on the New York Times business pages. * A majority of the members of the European Central Bank's influential Governing Council are increasingly uncomfortable with the central bank's growing financial exposure to Greece, according to people with knowledge of the group's discussions.

  19. Show article details.

    J&J Changes 'Compassionate' Drug Use

    DJ Business News – 12:15 AM ET 05/07/2015

    Under increasing pressure to expand access to experimental medicines, Johnson& Johnson has arranged for an independent panel to review requests from seriously ill patients who want to try an unapproved drug even if they aren't participating in the drug's testing. The committee of doctors, bioethicists and patient representatives organized by the New York University School of Medicine will consider the hundreds of requests that J&J receives each year from patients who...

  20. Show article details.

    Johnson & Johnson Announces NYU School of Medicine Partnership To Evaluate Compassionate Use of Investigational Medicines

    PR Newswire – 12:01 AM ET 05/07/2015

    NEW BRUNSWICK, N.J., May 7, 2015Johnson & Johnson (JNJ) today announced a first-of-its-kind partnership that enlists a third party to review requests made to the Janssen Pharmaceutical Companies of Johnson & Johnson (JNJ) for compassionate use of its investigational medicines.

Page:

Today's and Upcoming Events

  • Jul
    14

    JNJ to announce Q2 earnings Before Market (Unconfirmed)

Past Events (last 90 days)

  • May
    21

    JNJ ex-Dividend for $0.75 on 5/21/2015

    • Announce Date: 4/23/2015
    • Record Date: 5/26/2015
    • Pay Date: 6/9/2015
  • Apr
    23

    Shareholders Meeting

  • Apr
    14

    JNJ Earnings Conference Call at 8:30 AM Listen

Data provided by Wall Street Horizon, Inc. © 2015

Technical Events

Technical Analysis

PROVIDED BY TRADING CENTRAL
As with all your investments through Fidelity, you must make your own determination whether an investment is appropriate for you. Fidelity is not recommending or endorsing this security by making it available to customers. You should conduct research and perform a thorough investigation as to the characteristics of any securities you intend to purchase. Before investing, you should read the prospectus, offering circular, indenture, or similar document carefully for a full description of the product, including its features and risks, to determine whether it is an appropriate investment for your investment objectives, risk tolerance, financial situation and other individual factors, and be sure to re-evaluate those factors on a periodic basis.

Performance data shown represents past performance, which is no guarantee of future results. Current performance may be higher or lower than the performance data quoted. Yield and return will vary, therefore, you may have a gain or loss when you sell your shares.


Stock markets are volatile and can decline significantly in response to adverse issuer, political, regulatory, market, or economic developments. Growth stocks can be more volatile than other types of stocks. Value stocks can continue to be undervalued by the market for long periods of time. Foreign securities are subject to interest-rate, currency-exchange-rate, economic, and political risks, all of which are magnified in emerging markets. Illiquidity is an inherent risk associated with investing in real estate and REITs. There is no guarantee the issuer of a REIT will maintain the secondary market for its shares and redemptions may be at a price which is more or less than the original price paid. Closed-end funds can trade at a discount to their NAV. Shareholders of Master Limited Partnerships may be treated as partners for tax purposes. Partnerships issue a Schedule K-1 (Form 1065) rather than a Form 1099 form for tax purposes. It lists the partner's share of income, deductions, credits, etc. Speak with your tax advisor to determine how this may affect you. A royalty trust is a type of corporation, mostly in the United States or Canada, usually involved in oil and gas production or mining. Royalty trusts may have special tax treatment, so you should consult a tax advisor on the potential tax consequences of investing in them.

News, commentary and events are from third-party sources unaffiliated with Fidelity. Fidelity does not endorse or adopt their content. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from their use.

Any data, charts and other information provided on this page are intended for research purposes to help self-directed investors evaluate many types of securities including, but not limited to common stocks, American Depository Receipts, Master Limited Partnerships, real estate investment trusts. traditional preferred stock, trust preferred securities, third-party trust certificates, convertible securities, mandatory convertible securities and other exchange-traded equity and/or debt securities. Criteria and inputs entered, including the choice to make security comparisons, are at the sole discretion of the user and are solely for the convenience of the user. Analyst opinions, ratings and reports are provided by third-parties unaffiliated with Fidelity. All information supplied or obtained from this page is for informational purposes only and should not be considered investment advice or guidance, an offer of or a solicitation of an offer to buy or sell a security, or a recommendation or endorsement by Fidelity of any security or investment strategy. Fidelity does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from its use.